Successful treatment of low turnover osteoporosis resulting from prolonged reserpine therapy with intermittent calcitonin and phosphate therapy.
Coherence therapy, popularly known by the acronym ADFR (Activate, Depress, Free, Repeat), was designed to increase bone mass in osteopenic patients. Accordingly, we report a case of a hypogonadal male with histologically proven low bone turnover osteoporosis and a progressive vertebral fracture syndrome, who responded favorably to ADFR treatment with the use of salmon calcitonin and inorganic phosphate. Dramatic increments in bone mass were observed during a 68-month period of therapy. Serial quantitative computerized tomography demonstrated a 146% increase from baseline in bone mineral density for the first 30 months of treatment, and dual energy radiography yielded a 36.5% increase for the subsequent 31-68 months. Furthermore, no episode of fracture occurred since coherence therapy was initiated.
Armamento-Villareal
R C
RC
Division of Bone and Mineral Diseases, Washington University Medical Center, St. Louis, Missouri.
Avioli
L V
LV
D000328:Adult; D015519:Bone Density / Q000187:drug effects; D002116:Calcitonin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy*; D010710:Phosphates / Q000627:therapeutic use*; D012110:Reserpine / Q000009:adverse effects*; D013122:Spinal Diseases / Q000139:chemically induced / Q000188:drug therapy
D010710:Phosphates; C028815:salmon calcitonin; D012110:Reserpine; D002116:Calcitonin